Ruolo dei polimorfismi del CYP450 1A2 negli eventi avversi da clozapina: uno studio osservazionale.

TL;DRAbstract

Objectives: The genetically polymorphic enzyme cytochrome P450 (CYP) 1A2
\ncontributes to the biotransformation of the antipsychotic drug clozapine (CLO). Two
\npolymorphisms are known to affect significantly 1A2 activity: 1A2*1F which increase
\nmetabolism and 1A2*1C which decrease it. These SNPs, located in the promoter region
\nof the gene, may be responsible of a different CYP1A2 mRNA expression and could
\nhelp to explain interindividual differences in enzyme activity. Aim of these research
\nwas to evaluate the impact of these polymorphisms on CLO pharmacokinetics and on
\nthe occurrence of adverse reactions (ADRs).
\nMethods: All enrolled subjects were patients treated with CLO in our department
\nduring the period 2008-2009. Inclusion criteria for case-group were: diagnosis of
\npsychotic disorder, normal liver and renal function, absence of concomitant diseases,
\noccurrence of significant CLO-induced ADRs. Patients who assumed CYP1A

Chat with Paper

AI Agents for this Paper